Several analysts have recently updated their ratings and price targets for Neon Therapeutics (NASDAQ: NTGN):

  • 6/8/2019 – Neon Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Neon Therapeutics Inc. is a clinical-stage immuno-oncology company. It engaged in developing neoantigen-based therapeutics for the treatment of cancer by directing the immune system. The company’s product pipeline consists of NEO-PV-01, NEO-PTC-01 and NEO-SV-01 which are in clinical stage. Neon Therapeutics Inc. is based in Cambridge, United States. “
  • 6/7/2019 – Neon Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $6.25 price target on the stock. According to Zacks, “Neon Therapeutics Inc. is a clinical-stage immuno-oncology company. It engaged in developing neoantigen-based therapeutics for the treatment of cancer by directing the immune system. The company’s product pipeline consists of NEO-PV-01, NEO-PTC-01 and NEO-SV-01 which are in clinical stage. Neon Therapeutics Inc. is based in Cambridge, United States. “
  • 6/3/2019 – Neon Therapeutics is now covered by analysts at Mizuho. They set a “buy” rating and a $21.00 price target on the stock.
  • 5/30/2019 – Neon Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $10.00 price target on the stock.

NTGN stock traded down $0.09 during mid-day trading on Wednesday, hitting $4.91. The company had a trading volume of 244,900 shares, compared to its average volume of 144,045. The firm has a market cap of $141.65 million and a price-to-earnings ratio of -0.89. The company has a debt-to-equity ratio of 0.09, a quick ratio of 7.30 and a current ratio of 7.30. Neon Therapeutics Inc has a 12 month low of $4.20 and a 12 month high of $16.23.

Neon Therapeutics (NASDAQ:NTGN) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.03). Analysts forecast that Neon Therapeutics Inc will post -2.67 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the business. Citigroup Inc. increased its stake in shares of Neon Therapeutics by 157.9% in the first quarter. Citigroup Inc. now owns 4,286 shares of the company’s stock worth $28,000 after purchasing an additional 2,624 shares in the last quarter. Marshall Wace North America L.P. purchased a new position in shares of Neon Therapeutics in the first quarter worth about $49,000. American International Group Inc. increased its stake in shares of Neon Therapeutics by 124.4% in the first quarter. American International Group Inc. now owns 9,323 shares of the company’s stock worth $60,000 after purchasing an additional 5,169 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Neon Therapeutics by 100.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 10,000 shares of the company’s stock worth $65,000 after purchasing an additional 5,000 shares in the last quarter. Finally, Rhumbline Advisers purchased a new position in shares of Neon Therapeutics in the first quarter worth about $78,000. 69.57% of the stock is currently owned by institutional investors and hedge funds.

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

See Also: What is Compound Interest?

Receive News & Ratings for Neon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.